These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 12820365)

  • 21. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.
    Thomas AL; Morgan B; Horsfield MA; Higginson A; Kay A; Lee L; Masson E; Puccio-Pick M; Laurent D; Steward WP
    J Clin Oncol; 2005 Jun; 23(18):4162-71. PubMed ID: 15867205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma.
    Reinblatt M; Pin RH; Bowers WJ; Federoff HJ; Fong Y
    Ann Surg Oncol; 2005 Dec; 12(12):1025-36. PubMed ID: 16244806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
    Drevs J; Müller-Driver R; Wittig C; Fuxius S; Esser N; Hugenschmidt H; Konerding MA; Allegrini PR; Wood J; Hennig J; Unger C; Marmé D
    Cancer Res; 2002 Jul; 62(14):4015-22. PubMed ID: 12124335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Angiogenesis and hematologic malignancy].
    Zini JM; Tobelem G
    Bull Cancer; 2007 Jul; 94 Spec No():S241-6. PubMed ID: 17846010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colorectal cancer and antiangiogenic therapy: what can be expected in clinical practice?
    Mancuso A; Sternberg CN
    Crit Rev Oncol Hematol; 2005 Jul; 55(1):67-81. PubMed ID: 15890525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Angiogenesis and antiangiogenic cancer therapy].
    Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
    Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiangiogenic cancer therapy.
    Cao Y
    Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Tumor angiogenesis: new approaches to cancer therapy].
    Marmé D
    Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumoral angiogenesis: review of the literature.
    Khosravi Shahi P; Fernández Pineda I
    Cancer Invest; 2008 Feb; 26(1):104-8. PubMed ID: 18181052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in experimental animal models to the reality of clinical use].
    Plavetić ND; Letilović T; Vrbanec D
    Lijec Vjesn; 2003; 125(9-10):260-5. PubMed ID: 15038217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarkers for angiogenesis and antiangiogenic drugs in clinical oncology.
    Bertolini F
    Breast; 2009 Oct; 18 Suppl 3():S48-50. PubMed ID: 19914542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
    Kurschat P; Eming S; Nashan D; Krieg T; Mauch C
    Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiogenesis--a new target for future therapy.
    Pandya NM; Dhalla NS; Santani DD
    Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma.
    Das B; Yeger H; Tsuchida R; Torkin R; Gee MF; Thorner PS; Shibuya M; Malkin D; Baruchel S
    Cancer Res; 2005 Aug; 65(16):7267-75. PubMed ID: 16103078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential role of soluble VEGFR-1 in antiangiogenesis therapy for cancer.
    Yang F; Jin C; Jiang YJ; Li J; Di Y; Fu DL
    Expert Rev Anticancer Ther; 2011 Apr; 11(4):541-9. PubMed ID: 21504321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
    Drevs J; Zirrgiebel U; Schmidt-Gersbach CI; Mross K; Medinger M; Lee L; Pinheiro J; Wood J; Thomas AL; Unger C; Henry A; Steward WP; Laurent D; Lebwohl D; Dugan M; Marmé D
    Ann Oncol; 2005 Apr; 16(4):558-65. PubMed ID: 15705616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AE-941 (Neovastat): a novel multifunctional antiangiogenic compound.
    Gingras D; Batist G; Béliveau R
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):341-7. PubMed ID: 12113101
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-VEGF therapy: the search for clinical biomarkers.
    Longo R; Gasparini G
    Expert Rev Mol Diagn; 2008 May; 8(3):301-14. PubMed ID: 18598109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiangiogenic anticancer strategy based on nanoparticulate systems.
    Yoncheva K; Momekov G
    Expert Opin Drug Deliv; 2011 Aug; 8(8):1041-56. PubMed ID: 21585229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.